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Background. Plasmodium malariae is considered a minor malaria parasite, although its global disease burden is underappre-
ciated. The aim of this study was to develop an induced blood-stage malaria (IBSM) model of P. malariae to study parasite biology, 
diagnostic assays, and treatment.
Methods. This clinical trial involved 2 healthy subjects who were intravenously inoculated with cryopreserved P. malariae–
infected erythrocytes. Subjects were treated with artemether-lumefantrine after development of clinical symptoms. Prior to anti-
malarial therapy, mosquito-feeding assays were performed to investigate transmission, and blood samples were collected for rapid 
diagnostic testing and parasite transcription profiling. Serial blood samples were collected for biomarker analysis.
Results. Both subjects experienced symptoms and signs typical of early malaria. Parasitemia was detected 7 days after inocula-
tion, and parasite concentrations increased until antimalarial treatment was initiated 25 and 21 days after inoculation for subjects 1 
and 2 respectively (peak parasitemia levels, 174 182 and 50 291 parasites/mL, respectively). The parasite clearance half-life following 
artemether-lumefantrine treatment was 6.7 hours. Mosquito transmission was observed for 1 subject, while in vivo parasite tran-
scription and biomarkers were successfully profiled.
Conclusions. An IBSM model of P. malariae has been successfully developed and may be used to study the biology of, diagnostic 
testing for, and treatment of this neglected malaria species.
Clinical Trials Registration. ACTRN12617000048381.
Keywords. Plasmodium malariae; induced blood-stage malaria; transmission; diagnostics; transcriptomics; biomarkers; CHMI; 
pLDH.
Recent global malaria control efforts have appropriately focused 
on the most virulent Plasmodium species infecting humans, 
Plasmodium falciparum, with lesser efforts on the second most im-
portant species, Plasmodium vivax. However, the effort to eradi-
cate malaria necessitates an understanding of all infective species. 
In comparison to P. falciparum and P. vivax, our understanding of 
Plasmodium malariae biology and pathogenesis is very limited. 
While the majority of malaria morbidity and mortality is associated 
with P. falciparum and P. vivax, P. malariae as a coinfecting path-
ogen is found in 4%–24% of cases and has a wide geographical 
distribution [1–3]. P. malariae can cause prolonged and often sub-
patent infection [4] and chronic renal dysfunction [5], and it may 
modulate the clinical course and transmission of other species [6]. 
Recent sequencing studies of a P. malariae draft genome [7] and 
establishment of a good quality reference genome [8] heralds a 
much greater understanding of this neglected tropical pathogen. 
However, many questions remain about the biology of this species, 
the efficacy of current control measures, the dynamics of transmis-
sion, the performance of routine diagnostic testing [9, 10], and the 
efficacy of standard antimalarial treatments [11–13].
Volunteer infection study (VIS) clinical trials represent a pow-
erful approach to assess the efficacy of malaria vaccines and anti-
malarial drugs [14–16]. VIS trials allow for detailed evaluation of 
parasite growth kinetics, pharmacodynamics of the antimalarial 
activity of candidate drugs, and parasite transmission to vector 
mosquitoes. They also provide an opportunity to evaluate par-
asite biology and characterize host immunological responses in 
a controlled environment. Data from such studies can provide 
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information for the development of diagnostic tests, vaccines, and 
drugs. While reliable VIS models have been developed for P. fal-
ciparum and P. vivax, none have been developed for P. malariae. 
The aim of this study was to develop an induced blood-stage ma-
laria model (IBSM) with a wild isolate of P. malariae.
METHODS
Study Design
This was a clinical trial involving 2 sequential cohorts of 1 subject 
each (clinical trials registration ACTRN12617000048381). The 
study was approved by the QIMR Berghofer Medical Research 
Institute Human Research Ethics Committee and conducted in 
accordance with the Declaration of Helsinki. Subjects provided 
written informed consent prior to participation in the study. The 
primary objective was to determine the safety and infectivity of 
the P. malariae isolate in healthy subjects following inoculation 
with blood-stage parasites. The secondary objectives were to 
define parasite growth curves and clearance profiles after admin-
istration of the antimalarial drug artemether-lumefantrine and 
to investigate the infectivity of parasites to vector mosquitoes. 
The exploratory objectives were to evaluate the in vivo pattern 
of gene transcription of P. malariae, to establish host and parasite 
biomarker dynamics during early stage infection, and to evaluate 
a commercially available rapid diagnostic test (in cohort 2 only).
Study Subjects
Healthy adults aged 18–55 years were eligible for participation. 
Subjects were required to be malaria naive, blood group A or 
AB, and Rh(D) positive. A full list of the inclusion/exclusion cri-
teria for this study is included in the Supplementary Materials.
P. malariae Inoculum
The P.  malariae isolate (HMPBS-Pm) used in this study was 
derived from blood donated by a traveler returning from 
Guinea, Africa, who presented to the Royal Brisbane and 
Women’s Hospital with symptomatic, polymerase chain reac-
tion (PCR)–confirmed P.  malariae infection. The genome of 
this isolate has been sequenced and has previously been com-
pared to the P. malariae reference genome [8]. The production 
of parasite inoculum banks from donor blood specimens has 
been previously described for P. falciparum and P. vivax [17, 18].
Study Procedures
After intravenous injection of parasites on study day 0, subjects 
were monitored by daily telephone calls for the first 5  days. 
From day 6 onward, subjects visited the study site daily for clin-
ical monitoring of adverse events (AEs), signs and symptoms 
of malaria parasite infection, and blood sampling for measure-
ment of the parasitemia level.
Antimalarial treatment with artemether-lumefantrine was 
instituted following development of clinical symptoms consistent 
with malaria parasite infection or if the parasitemia level exceeded 
200 000 parasites/mL, a safety threshold based on previous IBSM 
studies [19]. Prior to treatment, mosquito feeding assays were 
performed, and blood samples were collected for transcrip-
tomic analysis, biomarker studies, and rapid diagnostic tests. 
Treatment consisted of 6 doses (administered 12 hours apart) 
of artemether-lumefantrine (Riamet, Novartis Pharmaceuticals 
Australia). Safety assessments and blood sampling to monitor the 
parasitemia level were conducted twice daily until parasite clear-
ance and then at protocol-specified visits until 3  months after 
treatment, to monitor for any signs of recrudescence.
Safety and Parasitemia Assessment
Safety monitoring of subjects included recording adverse events, 
measuring vital signs, physical examination, electrocardiog-
raphy (ECG), and measuring clinical laboratory parameters (via 
hematologic studies; clinical chemistry analyses, including creat-
inine studies; and urinalysis, including urinary protein studies).
The parasitemia level was measured using quantitative PCR 
targeting the gene encoding P.  malariae 18S ribosomal RNA 
(rRNA), as previously described [17]. Search of the P. malariae 
genome confirmed that this Plasmodium species carries 2 cop-
ies of this gene target.
Calculation of Parasite Reduction Ratio (PRR)
The PRR and corresponding parasite clearance half-life were 
estimated using the slope of the optimal fit for the log-linear 
relationship of the decay in parasitemia level following arte-
mether-lumefantrine treatment, as previously described [20].
Mosquito Feeding Assays
Transmission of gametocytes to Anopheles stephensi mosquitoes 
was evaluated using a direct skin feeding assay (DFA) and a di-
rect membrane feeding assay (DMFA) as previously described 
for P.  falciparum [21]. Mosquito midguts were dissected and 
tested for transmission positivity, using light microscopy with 
mercurochrome staining and also using quantitative PCR tar-
geting the gene encoding P. malariae 18S rRNA.
Biomarker Dynamics Assessment
P. falciparum histidine-rich protein 2 (HRP2), pan-genus lactate 
dehydrogenase (LDH), P.  vivax LDH, and human C-reactive 
protein (CRP) were quantified in blood samples collected at 
various time points, using the recently developed Q-plex array 
enzyme-linked immunosorbent assay kit (Quansys Biosciences, 
Logan, UT) [22]. Untransformed quantitative parasitemia and 
quantitative biomarker measurements were correlated using a 
Spearman correlation.
Assessment of Rapid Diagnostic Testing
Rapid diagnostic testing was performed using the lateral flow 
antigen detection test CareStart Malaria HRP-2/pLDH (Pf/pan) 
Combo Test (Apacor, Berkshire, United Kingdom). Blood spec-
imens collected at the peak parasitemia level prior to treatment 
were tested as per manufacturer guidelines.
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Assessment of P. malariae Transcription Profile
A 20-mL blood sample collected at the peak parasitemia 
level prior to treatment was depleted of leukocytes by using 
a Plasmodipur push column, and infected erythrocytes were 
concentrated using a Percoll gradient [23]. RNA was extracted 
and complementary DNA synthesized using a SMART-seq2 
kit (Clonetech/Takara) with 32 cycles of amplification and 
PhiX bacteriophage as a control. The library was sequenced on 
a MiSeq (150-bp reads) and a HiSeq 2500 Illumina machine 
(125-bp paired-end reads). Sequence reads from the subject 
were excluded by alignment against the H.  sapiens HS19 ref-
erence genome, using BWA as part of an automatic pipeline 
at the Wellcome Sanger Institute. Parasite messenger RNA 
reads were mapped against the P.  malariae reference genome 
PmUG01 [8] from geneDB.org, using STAR default settings 
[24]. Visualization was performed in BamView [25] after trans-
forming the read file into the BAM format by using SAMtools 
[26]. P. malariae reads were compared to existing P. falciparum 
data to describe the pattern of gene transcription and deter-
mine the developmental stage of parasites. Correlation to the 
P. falciparum data set [27, 28] from PlasmoDB was performed 
in R, using the corrgram function. To enable the comparison, 
1:1 orthologs between P. falciparum and P. malariae were deter-
mined by orthoMCL [29]. To better assess the more variable 
subtelomeric gene families, the genomic reads of the inoculum 
isolate HMPBS-Pm (accession ERS567899) were assembled 
using MaSuRCA (default parameters) [30]. Genome annotation 
was performed with Companion [31], using P. malariae UG01 
as a reference (parameter Augustus ab initio set to 0.2).
RESULTS
Subjects
A total of 8 subjects were screened for eligibility, and 2 subjects 
were enrolled in the study (1 in each cohort). Subject 1 and sub-
ject 2 were healthy white men aged 24 and 18 years, respectively.
Safety
A total of 35 AEs were reported (Table 1), the majority of which 
(30 of 35 [85.7%]) were attributed to P. malariae infection. The 
remaining AEs were either attributed to direct skin feeding with 
mosquitoes (2 of 35) or considered to be unrelated to study pro-
cedures (3 of 35). Most AEs (27 of 35 [77.2%]) were mild in 
severity, with the remaining AEs moderate in severity. None of 
the AEs reported in this study were classified as serious. Both 
subjects experienced chills, fatigue, headache, malaise, myalgia, 
and nausea during the study. Fever and transient moderate neu-
tropenia were also recorded for both subjects and were consis-
tent with malaria parasite infection.
Parasitemia
Parasitemia was first detected 7 days after inoculation, and the 
level increased at a similar rate in both subjects until antimalarial 
treatment was initiated 25 and 21 days after inoculation for sub-
ject 1 and subject 2, respectively (Figure 1). Parasitemia levels 
at the time of treatment were 140 890 and 50 291 parasites/mL, 
respectively. Clearance of parasitemia occurred following arte-
mether-lumefantrine treatment in both subjects, with no recru-
descence observed up to 3 months after treatment. Furthermore, 
there was no evidence of persisting gametocytemia, as would be 
indicated by persistent detection of P. malariae DNA. The peak 
parasitemia level recorded for subject 1 was 174 182 parasites/
mL, which occurred 4 hours after treatment. The parasitemia 
level at the time of treatment was the highest level recorded for 
Table 1. Adverse Events Recorded for Each Subject
Adverse Event
Events, No.
Subject 1 Subject 2
Abdominal discomfort 0 2
Arthralgia 1 0
Chills 1 1
Cough 0 1
Decreased appetite 0 1
Dizziness 1 0
Fatigue 1 2
Furuncle 0 1
Headache 1 4
Influenza-like illness 1 0
Malaise 1 1
Myalgia 2 1
Nausea 1 2
Neutrophil count decrease 1 1
Puncture site induration 1 1
Pyrexia 1 3
Upper respiratory tract infection 0 1
Total 13 22
Subject 1
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Figure 1. Parasitemia profile for each subject. Vertical dotted lines indicate the 
day that treatment with artemether-lumefantrine was initiated (day 25 for subject 
1 and day 21 for subject 2).
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subject 2. The overall PRR was 143.4 (95% confidence interval 
[CI], 73.7–278.7), and the parasite clearance half-life was 6.70 
hours (95% CI, 5.91–7.74). Parasite clearance occurred at a sim-
ilar rate in each subject.
Transmission to Mosquitoes
DFAs and DMFAs were performed just prior to antimalarial 
treatment (25 and 21 days after inoculation  for subject 1 and 
subject 2 respectively). The average feeding rate of mosqui-
toes was high (minimum, 95.1%), and the mortality rate was 
<26% for all assays (Supplementary Table 1). Transmission of 
parasites to mosquitoes was detected for subject 1, with 1 of 34 
mosquitoes (2.9%) becoming infected following the DFA. Light 
microscopy confirmed that the infected mosquito contained a 
single oocyst. No transmission was observed with the DFA for 
subject 2 or with the DMFA for either subject.
Biomarker Dynamics and Rapid Diagnostic Testing
Serial blood sampling for evaluation of biomarkers of malaria 
parasite infection was performed for subject 2.  Quantitative 
analyses revealed that HRP2 and P. vivax pLDH remained un-
detectable throughout the course of parasitemia. Pan-genus 
pLDH first became detectable on day 13 after inoculation, at a 
parasitemia level of 137 parasites/mL (Figure 2). The pan-genus 
pLDH level was strongly correlated with the parasitemia level 
(R = 0.78; 95% CI, .52–.91), although there was an evident time 
lag in biomarker response. CRP levels increased with parasit-
emia levels, although the relationship was weaker (R  =  0.13; 
95% CI, −.32–.53; Figure 2). The time lag in biomarker response 
was more pronounced for CRP; peak values occurred 36 hours 
after initiation of treatment, and values remained elevated after 
parasite clearance. A CareStart Malaria HRP-2/pLDH (Pf/pan) 
rapid diagnostic test performed on day 21 after inoculation, at a 
parasitemia level of 50 291 parasites/mL, had a negative result.
Transcriptome Analysis
A blood specimen collected from subject 1 at the time of the 
peak pretreatment parasitemia level (140 890 parasites/mL) un-
derwent RNA sequencing (RNA-Seq). Extraction of the RNA 
generated 100  ng to 3.3  µg of total complementary DNA for 
high-throughput sequencing. The raw reads can be found under 
the sample accession number ERS1699009. The accession num-
bers of the sequencing reads for the Illumina MiSeq and HiSeq 
2500 are ERX2597961 and ERR2690580, respectively.
A large proportion of sequenced reads corresponded to 
the host (51.2%), which were excluded automatically by the 
Wellcome Sanger Institute sequencing pipeline, or to the PhiX 
control (25.6%); 5.8% of sequenced reads were mapped against 
P.  malariae. Of these, approximately 75% corresponded to 
rRNA. While the mRNA yield of P. malariae was low (1.45%), 
deep sequencing (>260 million reads) enabled approximately 3.8 
million informative parasite-derived reads to be obtained that 
clearly mapped to the P. malariae genome. This represents a the-
oretical coverage of 33 times all coding sequences. If normalized 
coverage (in reads per kilobase of transcript, per million reads 
mapped [RPKM]) detection thresholds of 5 or 10 are assumed, 
expression was detected for 948–1463 genes (Figure 3).
The RPKM raw reads count per gene for the 15 genes with 
highest expression are shown in Supplementary Table 2. Two 
of these (PmUG01_14016600 and PmUG01_14018200) encode 
gamete antigen 27/25. The P. malariae genome includes 20 ap-
parently intact copies of this gene, compared with a single copy 
in other examined Plasmodium species [8]. Of these 20 copies, 
only 3 were highly expressed, with comparatively low expres-
sion in others (Figure 4).
Parasite development stages within the sample were deter-
mined by comparing gene expression profiles against 2 time-
course data sets from P.  falciparum (Supplementary Figure 
1). Correlations were low (0.12–0.37) but peaked against the 
32-hour intraerythrocytic form (0.35) and gametocyte II (0.37).
The structure of expressed genes could be clearly resolved 
by visual inspection in which mRNA reads were compared to 
PmUG01 reference genome predictions (Figure 3A). Expression 
signals with peaks in the 5′ untranslated region (UTR) or 5′ inter-
genic regions were seen in coverage for several highly expressed 
genes (Figure 3B–D). In some cases, discrete coverage distal to an 
existing gene prediction was indicative of a novel noncoding RNA 
(Figure 3B). In other cases, the 5′ UTR coverage bias appeared 
to reflect overamplification during library production (Figure 
3C). No evidence of a long UTR or novel noncoding RNA was 
found in the regions of higher expression when comparing the 
P. malariae genome PmUG01_05020900 to published data sets 
on PlasmoDB for P.  falciparum orthologs (PF3D7_0825100; 
Figure 3D). RNA-Seq data were also used to correct the intron-
exon structure of predicted genes in the current annotation of 
the reference genome (Figure 3E). It was possible to perform an 
exploratory analysis of expression of predicted exported proteins 
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Figure 2. Biomarker results for subject 2. The vertical dotted line indicates the 
day that treatment with artemether-lumefantrine was initiated (ie, day 21). CRP, 
C-reactive protein; pLDH, parasite lactate dehydrogenase. 
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that may contribute to parasite virulence. The P. malariae genome 
published by Rutledge et al [8] reported 2 new tandemly organ-
ized multigene families (fam-l and fam-m) that share structural 
similarity with a P. falciparum merozoite surface protein, encoded 
by Rh5 (PF3D7_0424100), that is essential for erythrocyte inva-
sion. We were unable to find evidence for expression of any fam-l 
and fam-m pairs, even when RNA-Seq data were matched to an 
assembled and annotated genome from the study isolate. In con-
trast, evidence of expression (RPKM, >10) was found for other 
subtelomeric gene family members, of which 22 encoded puta-
tively exported proteins, including 8 PHIST proteins and 1 STP1. 
Ten pir genes also appeared to be expressed, but all had a RPKM 
value of < 5, based on the PmGN01 annotation.
DISCUSSION
Inoculation of healthy subjects with the P. malariae HMPBS-Pm 
clinical isolate resulted in a safe and reproducible course of 
parasitemia that was well tolerated. Specifically, there was no 
evidence of renal impairment or late recurrent infection in the 
3  months following treatment. The overall nature, frequency, 
and severity of AEs was similar to that reported following exper-
imental inoculation with blood stages of other Plasmodium spe-
cies, where mild-to-moderate symptoms attributable to malaria 
were observed with increasing parasitemia levels [17, 18]. 
Significantly, no AEs were classified as severe or serious, and no 
biochemical abnormalities were noted.
Parasite growth following inoculation was slower for P. malar-
iae, compared with that reported for P. falciparum or P. vivax [17, 
18], consistent with the slower 72-hour intraerythrocytic life cycle 
and smaller number of merozoite schizogony per cycle character-
istic of the species [32]. The pyrogenic threshold of P. malariae 
infection in this study was lower than that reported for histor-
ical case series from the malariotherapy era, where the median 
parasitemia at first fever was reported to range from 997 800 to 
2 664 000 parasites/mL [19]. This may be due to differences in 
interindividual infection tolerability, the strain of P. malariae, or 
increased subject monitoring in modern clinical trials.
Parasite clearance following administration of arte-
mether-lumefantrine was slower than that estimated for species 
with a shorter 48-hour intraerythrocytic life cycle. The parasite 
clearance half-life following artemether-lumefantrine treatment 
was 6.7 hours (95% CI, 5.91–7.74) in this study. As a compari-
son, a parasite clearance half-life of >5.0 hours is used to indi-
cate artemisinin resistance in P.  falciparum [33]. Nonetheless, 
standard-dose artemether-lumefantrine was effective, without 
evidence of recrudescence at follow-up 3  months after treat-
ment. However, there are reports of treatment failure in the lit-
erature [9, 13]. Postulated mechanisms of a refractory response 
of P.  malariae infection to artemether-lumefantrine include a 
relative reduction in drug exposure due to a prolonged parasite 
life cycle or delayed hepatic schizogony, parasite dormancy and 
reduced susceptibility to treatment, an undescribed hypnozoite 
stage, and genetic subpopulations with intrinsic drug resistance 
[11, 34]. Treatment success in this study may be related to a 
relatively low parasitemia level at the time of treatment or to 
the susceptibility of this P. malariae strain. In the absence of a 
hepatic stage of infection in the IBSM model, it is not possible 
to assess the effect of delayed hepatic schizogony or as-yet-un-
described hypnozoite forms.
The successful transmission of P.  malariae to mosquitoes 
confirms gametocytogenesis in the model. While only a single 
transmission episode occurred, the low rate of transmission is 
consistent with that for other Plasmodium species at low levels 
of parasitemia/gametocytemia and validates the model as a tool 
for the evaluation of parasite transmission [21]. Relatively little 
is known regarding the dynamics of P.  malariae gametocyte 
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Figure 3. Examples of read coverage determined by RNA sequencing analysis. 
The coverage plot represents the number of reads mapped over each base, plotted 
in black. RNA reads are mapped to the reference genome (long light gray rows; num-
bers indicate the position on the chromosome). White and dark gray bars represent 
predicted exons. Coverage without a predicted exon may represent an untranslated 
region (UTR), noncoding RNA (ncRNA), or missing exons in the reference genome. 
Read depth represents a guide to the degree of expression. A, Example of good gene 
coverage, with clear exon-intron boundaries and no mapped reads between exons 
(white bars). Coverage left and right are from UTRs. B, Example of a gene with low 
expression (left side; white bars) and expression approximately 4 kb downstream of 
putative ncRNA. C, Example of potential 5′UTR amplification as compared to the rest 
of the gene (dashed boxes). D, Example of overlapping expression (dashed boxes). The 
exon-intron boundaries are not clear, and expression appears to be in between exons 
of 1 gene. This may be due to an overlapping UTR of the neighbor gene or ncRNA on 
the reverse strand. E, Example of gene correction with the help of RNA sequencing 
analysis. Two new exons (dark gray bars in dashed box) can be added to the existing 
13 predicted exons (white bars) within the reference genome.
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commitment and transmission [19]. Significantly, P.  malar-
iae coinfection has been implicated in enhanced P. falciparum 
gametocytogenesis, suggesting that this species could potentiate 
transmission of more-virulent disease [35–37]. Such interac-
tions are exceedingly difficult to confirm in the field, making 
this model attractive to characterizing parasite biology and de-
veloping transmission-blocking interventions.
Pan-genus pLDH was the only Plasmodium-specific bio-
marker detected during the course of P.  malariae infection, 
and its levels were positively correlated with parasitemia levels. 
Results of rapid diagnostic testing targeting pan-genus pLDH 
were, however, negative, despite the presence of symptoms con-
sistent with malaria for 72 hours prior to testing. This is con-
sistent with previous reports of poor assay performance and an 
approximately 30% detection rate [10, 38, 39]. Although pan-ge-
nus pLDH appears to have the appropriate characteristics for 
a screening test, with a proportional increase with the parasit-
emia level and a relatively prompt clearance after treatment, the 
lack of sensitive rapid diagnostic testing for this Plasmodium 
species represents a challenge to case detection, true estimates 
of disease burden, and elimination efforts. An increased CRP 
level with an increasing parasitemia level reflects a nonspecific 
host response but is consistent with the correlation between this 
biomarker and disease severity in other Plasmodium species 
[40]. P. malariae infection in our study demonstrated different 
biomarker dynamics to those described in P. falciparum infec-
tion, with a relatively delayed lag period in pLDH positivity 
after the first observation of parasitemia, as well as a more pro-
nounced CRP signal [22]. While a larger sample is required to 
confirm these findings, such interspecies differences highlight 
the need for potentially different methods of detection. The 
high-throughput loop-mediated isothermal amplification assay 
has been demonstrated to be an effective and sensitive alterna-
tive detection method for other neglected Plasmodium species 
not readily identified by current rapid diagnostic tests, although 
application in P. malariae cases is limited, and field applications 
may be limited by cost [41].
Although exploratory assessment of the P. malariae transcrip-
tion profile in vivo isolated only a limited amount of mRNA for 
analysis, this proof of concept offers a number of prospects for 
further study of parasite biology and enabled the reference ge-
nome annotation for P. malariae to be refined. We did not find 
evidence of expression among the pir genes, which have been 
shown to have a major role in virulence in some other species 
[42, 43], or among the novel transmembrane protein families 
(fam-m or fam-l). Instead, other exported proteins, including 
PHISTs, were identified, suggesting these proteins may play a 
more prominent role in this species. Serial assessment of par-
asite transcription during the course of infection would also be 
informative and indicate whether antigenic variation or adhe-
sion molecule upregulation are parasite strategies permitting the 
prolonged, latent infections that have been previously described 
[4]. The identification of putative gametocyte gene transcripts 
may enable the development of a targeted reverse transcription 
PCR probe for more-sensitive analysis of gametocyte dynamics, 
as has been developed for both P. falciparum and P. vivax [44].
In conclusion, we have outlined an experimental system of 
P. malariae infection that offers the potential to study this ne-
glected tropical pathogen and subsequently accelerate the de-
velopment of diagnostic tests, drugs, and vaccines. The logistic 
challenges and financial costs of field-efficacy studies are even 
greater for P. malariae than for the more virulent malaria parasite 
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Figure 4. Expression of gamete antigen 27/25 (PmG27/25). Artemis view of the PmG27/25 locus. The boxes show the 22 PmG27/25 gene copies (white bars) and 2 
pseudogenes (gray bars). The top plot is raw coverage showing high-level expression of 3 gene copies, and the bottom plot is log-transformed coverage showing lower-level 
expression of the other copies.
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species, owing to relatively lower case numbers, challenges in 
case identification, and the relative frequency of coinfection. 
Nonetheless, the global effort to eradicate malaria necessitates an 
understanding of all infective species. The ability to undertake 
experimental study of P. malariae malaria in a dedicated clinical 
trial setting represents a significant resource, enhancing safety 
and enabling the design and conduct of well-controlled research.
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